Everand Logo

Welcome to Everand!

  • STAT

    AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

    by Adam Feuerstein and Matthew Herper Jun 25, 2019 1 minute
    Source: Kristoffer Tripplaar/Sipa/AP

    AbbVie said Tuesday it will acquire Allergan for $63 billion — the latest megamerger between two pharma giants seeking new ways to grow.

    The deal, combining two firms built by past acquisitions, represents. The big prize for AbbVie is Allergan’s franchise of aesthetics drugs, , which has annual sales of $3.6 billion.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
    Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
    The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks